Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: A brand-related issue?

Journal of Rheumatology

Volumn 44, Issue 3, 2017, Pages 368-

  Srinivasa, Amar ^a   Tosounidou, Sofia ^a   Gordon, Caroline ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; ANTIRHEUMATIC AGENT;

ABDOMINAL CRAMP; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; PREVALENCE; PRURITUS; RASH; RETINOPATHY; SELF REPORT; SYSTEMIC LUPUS ERYTHEMATOSUS; TINNITUS; UNITED KINGDOM; ABDOMINAL PAIN; CHEMICALLY INDUCED;

ABDOMINAL PAIN; ANTIRHEUMATIC AGENTS; DYSGEUSIA; DYSPEPSIA; HUMANS; HYDROXYCHLOROQUINE; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 85016423284     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.161063     Document Type: Letter

References (9)

1. Plaquenil availability, Lupus UK. [Internet. Accessed November 9, 2016.] Available from: www.lupusuk.org.uk/plaquenil-availability/
2. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 2010;69:20-8.
3. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243-63.
4. Alarcón GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, et al; LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72.
5. Costedoat-Chalumeau N, Galicier L, Aumaître O, Francès C, Le Guern V, Lioté F, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2013;72:1786-92.
6. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006;15:366-70.
7. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, Khamashta MA, Kim MY, Saxena A, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012;126:76-82.
8. Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol 1999;26:808-15.
9. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 2010;62:775-84.